Consistent with other findings, patients with ER-positive, HER2-low breast cancer who did not achieve pCR after NACT had a significantly greater recurrence risk than those who achieved pCR (P = 0.020)22,23. The gene discussed is ERBB2; the disease is breast carcinoma.